 | • レポートコード：MRC2203A832 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の喘息＆COPD治療薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤分類別（気管支拡張薬、抗炎症薬、モノクローナル抗体、併用薬）分析、疾患別（喘息、慢性閉塞性肺疾患（COPD））分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の喘息＆COPD治療薬市場規模：薬剤分類別（気管支拡張薬、抗炎症薬、モノクローナル抗体、併用薬） ・世界の喘息＆COPD治療薬市場規模：疾患別（喘息、慢性閉塞性肺疾患（COPD）） ・世界の喘息＆COPD治療薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AstraZeneca Plc、Boehringer Ingelheim GmbH、GlaxoSmithKline Plc、...） ・市場機会・将来の傾向 |
The Asthma and COPD drugs market is expected to witness a CAGR of 4.6% during the forecast period.
According to a research study by José Luis Izquierdo et al., published in European Respiratory Journal, March 2021, the study results found that allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There is a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission. Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat level, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection. Chronic obstructive pulmonary disease (COPD) patients have increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptor in small airways. According to a research study by Janice M. Leung et al., published in European Respiratory Journal, 2020, there is increasing evidence that COPD may be a risk factor for more severe COVID-19 disease. An analysis of comorbidities in 1,590 COVID-19 patients across China found that COPD carried an odds ratio of 2.681 for ICU admission, mechanical ventilation or death, even after adjustment for age and smoking. About 62.5% of severe cases had a history of COPD (compared with only 15.3% in non-severe cases) and 25% of those who died were COPD patients (compared with only 2.8% in those who survived).
Some of the factors that are driving the market growth include an increase in incidence and prevalence of asthma and COPD, technological advancements and growing geriatric population.
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable chronic lung disease which affects men and women worldwide. According to the World Health Organization (WHO) 2021 factsheet, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). Globally, increasing geriatric population is boosting the market growth. According to the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world. The number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 9.3% in 2020 to reach 16% by 2050. Hence, owing to the fact that asthma is a widely prevalent disease found in people over age 65, the growing geriatric population is expected to drive the market growth over the forecast period.
In addition, technological advancements are anticipated to provide the market lucrative opportunities. Limitations of traditional treatments, such as late onset of action and low efficacy, are projected to encourage the development of novel targeted drug, thereby boosting growth during the future period. For instance, in February 2021, Sanofi in collaboration with Regeneron Pharmaceuticals initiated a phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). The trial expected to complete in July 2024.
The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions and expansions to increase market share. For instance, In July 2020, Novartis AG received approval from European Commission (EC) for Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist (LABA) and a high-dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year. However, factors such as stringent government regulations for the product approval and side effects associated with drugs is expected to impede the market growth over the forecast period.
Key Market Trends
Asthma Segment is Expected to Hold Significant Market Share Over the Forecast Period
Asthma is considered to be one of the world’s most common diseases affecting the population and is also a life-threatening condition affecting patient’s regular breathing. It is a persistent condition that stretches and narrows the air passages of the lungs, causing constant assaults of breathlessness, bronchospasm, and reversible obstruction of airflow. Moreover, there is a large rise in the number of cigarettes, which contributes to asthma symptoms. In addition, the rise in industrialization has also contributed to an increase in the number of cases of asthma, which, over the forecast era, would drive the demand for asthma drugs.
Globally, the COVID-19 outbreak and the measures in response to it have had significant impacts on asthma control among children. According to a research study by Yuanmin Jia et al., published in the British Medical Journal (BMJ) May 2020, children with asthma are advised to continue good asthma management and take prescribed asthma medications as normal. According to a research study by Hashim T. et al., published in Journal of Medical Virology, March 2021, globally, the COVID-19 had a bad impact on the mental health of asthmatic patients especially in the beginning of the pandemic in 2020. However, asthmatic patients thought that they are more vulnerable for the disease than the others so many of them were following the preventive measures and committed to the quarantine to avoid infection. Airways and lung parenchyma are the main target of SARS-CoV-2 virus, concern was raised regarding the outcome in patients with chronic respiratory diseases such as asthma. According to a research study by P. Pignatti et al., published in the International Journal of Tuberculosis and Lung Disease, September 2020, patients with asthma in Northern Italy demonstrated a low occurrence of SARS-CoV-2 infection and a low number of asthma exacerbations. Most of the patients succeeded in following their asthma prescriptions despite the lockdown.
The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs. According to the World Health Organization (WHO) 2021 factsheet, Asthma is a major noncommunicable disease (NCD), affecting both children and adults. Globally, it has affected an estimated 262 million people in 2019 and caused 461,000 deaths. Enormous investment in the study of the asthma drugs accompanied by strategic collaborations such as mergers, acquisitions are business approaches commenced by the major companies in the asthma drugs market. For instance, in October 2019, the U.S Food and Drug Administration (FDA) has approved self-administration AstraZeneca’s asthma drug Fasenra, a pre-filled, single-use auto-injector. In March 2021, GlaxoSmithKline Plc in collaboration with Iqvia Pty Ltd initiated a phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial is expected to complete in October 2023. Similarly, in February 2021, AstraZeneca Plc in collaboration with Amgen Inc, initiated a phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma. The trial is expected to complete in September 2021. Thus, owing to above mentioned factors it is expected to drive the segment growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecasted Period
North America region is expected to dominate the asthma and COPD drugs market during the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.
In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8 percent of adults and 7 percent of children. About 20 million U.S. adults age 18 and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada’s 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs for the treatment of target disease, thereby boosting growth of this region.
Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.
In addition, the local presence of key pharmaceutical players, advanced healthcare infrastructure and increasing research and development activities in the development of novel therapies is boosting the market growth. For instance, in March 2021, in Mexico and United States, AstraZeneca Plc started a phase III clinical trial to assess the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care. The trial expected to complete in September 2023. In July 2021, AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the United States Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca Plc in collaboration with Amgen Inc. Thus, owing to above factors it is expected to drive the market growth over the forecast period.
Competitive Landscape
The Asthma and COPD Drugs Market is consolidated competitive. The industry is competitive in nature with key players involved in mergers and acquisitions, new product development, collaborations and partnerships, and expansion strategies to augment market penetration. Companies, like GlaxoSmithKline Plc, Merck & Co Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Novartis AG, among others, hold the substantial market share in the asthma and COPD drugs market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence and Prevalence of Asthma and Chronic Obstructive Pulmonary Disease (COPD)
4.2.2 Technological Advancements
4.2.3 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Government Regulations for the Product Approval
4.3.2 Side Effects Associated with Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Bronchodilators
5.1.1.1 Short Acting Beta-2 Agonists
5.1.1.2 Long Acting Beta-2 Agonists
5.1.1.3 Anti-cholinergic Agents
5.1.2 Anti-inflammatory Drugs
5.1.2.1 Oral and Inhaled Corticosteroids
5.1.2.2 Anti-leukotrienes
5.1.2.3 Phosphodiesterase Type-4 Inhibitors
5.1.2.4 Other Anti-inflammatory Drugs
5.1.3 Monoclonal Antibodies
5.1.4 Combination Drugs
5.2 By Indication
5.2.1 Asthma
5.2.2 Chronic Obstructive Pulmonary Disease
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca Plc
6.1.2 Boehringer Ingelheim GmbH
6.1.3 GlaxoSmithKline Plc
6.1.4 Novartis AG
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Pfizer Inc
6.1.7 Grifols SA
6.1.8 Merck & Co. Inc.
6.1.9 Sanofi S.A.
6.1.10 Sumitomo Dainippon Pharma Co., Ltd.
6.1.11 Teva Pharmaceutical Industries Ltd
6.1.12 Chiesi Farmaceutici S.p.A.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS